BCM
RETA

Bayesian Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Bayesian Capital Management’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-20,267
Closed -$616K – 1092
2022
Q2 		$616K Buy
+20,267
New +$605K 0.11% 270

Other funds holding RETA

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bayesian Capital Management's RETA Position: Q3 2022 in Review

Bayesian Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2022, closing a stake of 20,267 shares — an estimated $616K sold.

Bayesian Capital Management first reported a position in RETA in Q2 2022 and held it in 1 quarter. The position peaked at $616K in Q2 2022. 159 funds tracked by Wall St. Rank hold RETA as of Q3 2022.

  • Bayesian Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2022 after selling out during the quarter.
  • Bayesian Capital Management sold 20,267 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2022, an estimated $616K.
  • Bayesian Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2022 and held it in 1 quarter.
  • Bayesian Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $616K in Q2 2022.
  • 159 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2022.

Based on Bayesian Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.